X @Bloomberg

Strategic Acquisition - LEO Pharma agreed to acquire global rights for skin disease drug Spevigo from Boehringer [1] - The acquisition strengthens LEO Pharma's portfolio [1] IPO Plans - LEO Pharma is planning an IPO in 2026 [1] Industry Focus - LEO Pharma is a Danish dermatology specialist [1]